Their group of patients included those who had refractory pelvic pain and voiding dysfunction in a two-year time span at their institution. Patients who were only treated for voiding dysfunction were excluded. It was a retrospective Study to identify these patients. Diagnosis is made by those who responded to a pudendal nerve block on two occasions. Patients did have a staged implant with stage 2 being a two-week trial period.
She did a review the relevant anatomy and placement of the leads as many of the audience members are not familiar with this procedure.
A total of 10 patients with pelvic pain and voiding dysfunction were included in the staged trial. All were women with a mean age of 55.4. The duration of their symptoms the 6.6 years on average. Comorbidities were addressed with 60% having depression, 40% had fibromyalgia, and 100% had a bowel dysfunction. That previously failed conservative therapies like medications and help for physical therapy. Before moving on to narrow modulation, all the patients had a response two pudendal blocks. Her findings are as follows: nine out of 10 had a successful first day trial with more than 50% improvement in their pain and symptoms. These patients did proceed to stage 2. At a average eight month follow-up seven out of these nine were satisfied with their outcome.
In conclusion, in this small cohort of patients, there was a positive response to pudendal modulation and those patients with pelvic pain and voiding symptoms.
Presented by: Iryna Crescenze, MD, Urology FPMRS Fellow, University of Michigan